Myrbetriq, Myrbetriq Granules, Betmiga (mirabegron) is a small molecule pharmaceutical. Mirabegron was first approved as Myrbetriq on 2012-06-28. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder. The pharmaceutical is active against beta-3 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor and beta-2 adrenergic receptor. Myrbetriq's patents are valid until 2036-03-31 (FDA).
|Indication||overactive urinary bladder, urge urinary incontinence|
|Drug Class||Beta 3 adrenoreceptor agonist|